Navigation Links
FDA Approves Another New Drug to Fight Hepatitis C
Date:5/23/2011

MONDAY, May 23 (HealthDay News) -- The U.S. Food and Drug Administration on Monday approved Incivek (telaprevir), one of a new class of drugs, to fight chronic hepatitis C infection.

The approval comes after the agency gave a thumbs-up on May 13 to another drug in the same class, called Victrelis (boceprevir).

Both pills appear to help more people clear the virus from their system in a shorter time than older drugs for hepatitis C.

In three clinical trials sponsored by the drug's maker, Massachusetts-based Vertex Pharmaceuticals, a much higher percentage of patients responded favorably when Incivek was added to their care vs. the use of older drugs alone. The length of time needed to treat also fell, from 48 weeks to 24 weeks, the FDA said.

"With the approval of Incivek, there are now two important new treatment options for hepatitis C that offer a greater chance at a cure for some patients with this serious condition," Dr. Edward Cox, director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research, said in a statement. "The availability of new therapies that significantly increase responses while potentially decreasing the overall duration of treatment is a major step forward in the battle against chronic hepatitis C infection."

Experts working in the field agreed.

"Both patients and physicians are really excited about the approval of this drug, which represents a huge advance in the treatment of hepatitis C. It is expected to almost double the cure rate of this disease," said Dr. Douglas Dieterich, a professor of medicine in the division of liver diseases, at Mount Sinai School of Medicine in New York City.

"We are all very excited about the approval of a new treatment option for hepatitis C," added Dr. Joseph Rahimian, an infectious disease specialist at NYU Langone Medical Center. "This disease has been very difficult to treat, with limited therapeutic o
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. FDA approves new drug for advanced melanoma
2. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
3. FDA Approves 1st New Lupus Drug in More Than 50 Years
4. FDA Approves First 3D Mammogram Device
5. FDA Approves First Pacemaker Deemed Safe During MRIs
6. FDA Approves First Drug to Prevent Premature Births
7. Swiss agency approves clinical trial of UCI-created neural stem cell therapy
8. ACGME board approves final duty hour and supervision standards for resident education
9. FDA Approves 1st Oral Drug to Reduce MS Relapses
10. FDA approves Merz Pharmaceuticals Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm
11. Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Another New Drug to Fight Hepatitis C
(Date:6/18/2013)... June 18, 2013 David Connett, DO, ... Family Medicine for the College of Osteopathic Medicine of ... has been elected president of the Osteopathic Medical ... Brown Jr. appointed Connett, a 1984 alumnus of COMP, ... recently elected Connett to the position during a conference ...
(Date:6/18/2013)... N.Y., June 18, 2013 -- Lauren Sciences, a ... V-Smart nanovesicle platform technology, announced today that it ... Drug Delivery with its V-Smart Platform, and selected ... by MCD Group. , The report, ... Start-ups and Emerging Companies ," features companies MCD ...
(Date:6/18/2013)... enrolled their first patients in the ROADSTER Study, a ... to help clear blockages in carotid arteries and prevent ... in the United States are diagnosed with blockages, or ... blockages can slow or even stop blood flow to ... as a "brain attack." , Current treatment options ...
(Date:6/18/2013)... scrambling to gather data for the FDA to support ... injury in the United States. The University of Rochester ... the Journal of Neurotrauma that it might ... of one., Jeffrey J. Bazarian, M.D., M.P.H., an associate ... first to show that measuring a combination of two ...
(Date:6/18/2013)... system using a person,s DNA was announced as ... London Startup Competition, Europe,s largest technology conference. ... on University of Bristol research by its founders, ... Professor of Bioinformatics in the University,s Department of ... to be one of 16 finalists in the ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center among first to enroll patients for global carotid artery trial 2
... and research on guayule and lesquerella, two native Big Bend ... a Texas AgriLife Research scientist said. , Dr. Mike Foster, ... Center at Lubbock, said he is looking at the possibility ... Trans-Pecos and High Plains. Foster, who is located at the ...
... coverage isn,t reinstated, NEW YORK, Feb. 1 ... to cover Propofol under all circumstances,is getting louder. And ... call to file a consumer fraud lawsuit,against Aetna is ... York State issue has now become a national,campaign., ...
... on MySpace and Facebook, study finds , , FRIDAY, Feb. ... such as MySpace and Facebook have been singled out ... of the unwanted solicitation actually happens in chat rooms ... Even there, only 15 percent of children experience unwanted ...
... Patients with rheumatoid arthritis (RA), the most common ... other individuals to experience depression. Although depression in ... have examined whether rheumatologists and RA patients discuss ... in the February issue of Arthritis Care & ...
... American Heart Association,s ,Go Red for Women, Movement in ... ... As a leader in,cardiovascular treatment and the exclusive Bay Area "hometown" partner ... with the American Heart Association (AHA) to raise awareness,about heart disease, the ...
... (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth ... which demonstrated that ENBREL reduced C-reactive protein (CRP), a ... plaque psoriasis following 12 weeks of treatment. Median ... the ENBREL treated group compared to the placebo treated ...
Cached Medicine News:Health News:Growing markets bring potential for rubber and oilseed crops 2Health News:Growing markets bring potential for rubber and oilseed crops 3Health News:National Health Care Alliance Gains New Members Against Aetna's New Anesthesia Policy 2Health News:National Health Care Alliance Gains New Members Against Aetna's New Anesthesia Policy 3Health News:Social Networking Sites Safer Than IM or Chat Rooms 2Health News:Social Networking Sites Safer Than IM or Chat Rooms 3Health News:Depression not discussed during rheumatoid arthritis doctor visits 2Health News:Abbott 'Goes Red' to Educate Bay Area Women About Heart Disease 2Health News:Abbott 'Goes Red' to Educate Bay Area Women About Heart Disease 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
(Date:6/18/2013)... 18, 2013  Cataracts are the leading cause of ... of Ophthalmology, aging is the leading cause of eye ... natural lens. 22 million Americans age 40 and older ... to age, that number will increase over 30 million. ... iPads, smart-phones and computers, the demographic of ages 40 ...
(Date:6/18/2013)... , June 18, 2013  Decision Resources, ... firms for pharmaceutical and healthcare issues, announces that ... of the Middle East ... Tracker analyzes the challenges and opportunities to gaining ... international regions comprising 24 countries. The countries covered ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 ... Gilead Sciences, Inc. (NASDAQ: GILD ), Health Management ... (NASDAQ: IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ... readers may access these reports free of charge - including ... the links below. Gilead Sciences, Inc. Research Report ...
Breaking Medicine Technology:New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... a compression garment distributor, has announced that the redesigned ... An alternative to compression stockings , the garments ... knee and thigh, and resemble an athletic brace. ... been out for several years, but they recently made ...
... Calif., Dec. 14, 2011  Amgen (NASDAQ: AMGN ) ... tender offer, which expired at 12:00 midnight, New York City ... has accepted for purchase 83,333,333 shares of its common stock ... cost of approximately $5 billion, excluding fees and expenses relating ...
Cached Medicine Technology:BrightLife Direct Introduces Redesigned Solaris ReadyWrap Quick-Fit 2Amgen Announces Final Results of Its Tender Offer 2Amgen Announces Final Results of Its Tender Offer 3
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
Medicine Products: